ArticleFrontiers in oncology2020

Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.

Katsuo Usuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.